Literature DB >> 2871097

Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration.

R Wise, I A Donovan, C A McNulty, R Waldron, J M Andrews.   

Abstract

The pharmacokinetics of a 440 mg iv dose of teicoplanin were studied in six male volunteers. The levels of the compound were measured microbiologically in serum, blister fluid and urine. The mean serum level 0-5 h after injection was 44.6 mg 1(-1), falling to 3.6 mg 1(-1) at 49 h. The serum elimination half-life of teicoplanin when fitted to a two-compartment model was 34.2 h; a three-compartment model gave a longer half-life. The apparent distribution half-life was 1.5 h. Penetration into cantharides induced blister fluid was moderately fast, the mean maximum concentration (14.8 mg 1(-1)) occurring at 2.7 h, the mean percentage penetration being 77.4%. Urinary recovery of the drug was 48.3% by 96 h. The drug penetrated rapidly into the non-inflammed peritoneal fluid of 34 patients undergoing elective surgery. The percentage penetration being 40% within the first hour, and 94.6% over the period of the study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871097     DOI: 10.1016/0195-6701(86)90007-1

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  15 in total

1.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Penetration of tinidazole into skin blister fluid following its oral administration.

Authors:  A Klimowicz; A Nowak; S Bielecka-Grzela
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Two-stage penetration of a single oral dose of sulphadimethoxine into skin blister fluid.

Authors:  A Nowak; A Klimowicz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose.

Authors:  E Concia; M Cruciani; F Bartucci; L Arrigoni; A Longoni
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors:  F de Lalla; A Tramarin
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

6.  Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

Authors:  D R Guay; W M Awni; C E Halstenson; M T Kenny; W F Keane; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 8.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

9.  Plasma and skin blister fluid concentrations of trimethoprim following its oral administration.

Authors:  A Klimowicz; A Nowak; M Kadyków
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.

Authors:  D N Gilbert; C A Wood; R C Kimbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.